Wave Life Scienc Stock Price, News & Analysis

Wave Life Sciences (WVE), a clinical-stage biotech company specializing in RNA medicines, has announced its participation in the 2025 Jefferies Global Healthcare Conference. The company's President and CEO, Paul Bolno, MD, MBA, will engage in an analyst-led fireside chat on June 4, 2025, at 4:55 p.m. ET in New York City. The presentation will be accessible via live webcast through the company's investor relations website, with a replay available for a limited time afterward.

Wave Life Sciences (WVE) has appointed Dr. Christopher Wright as Chief Medical Officer. Dr. Wright, who will lead global development including medical, clinical and regulatory functions, brings extensive experience in drug development across multiple therapeutic areas. His background includes leadership roles at Ring Therapeutics, AavantiBio, Cyclerion Therapeutics, and Vertex Pharmaceuticals, where he co-wrote the first approved Breakthrough Status application. Dr. Wright holds an MD and MMSc from Harvard Medical School and a PhD from Vrije University.

As part of his appointment, Dr. Wright received a stock option grant for 300,000 ordinary shares at $5.94 per share, vesting over four years with 25% vesting on May 27, 2026, and the remainder in quarterly installments over three years.

Wave Life Sciences (WVE) has announced it will host a live webcast and conference call on Thursday, May 8, 2025, at 8:30 a.m. ET to discuss its first quarter 2025 financial results and provide business updates. The clinical-stage biotechnology company, which focuses on RNA medicines development, will make the webcast accessible through their investor relations website. Analysts can participate in the Q&A session by dialing (833) 630-1956 for domestic calls or (412) 317-1837 for international calls. An archived version of the webcast will be available on the company's website after the live event.

Wave Life Sciences (WVE) has announced positive 48-week data from its Phase 2 FORWARD-53 trial of WVE-N531, a treatment for Duchenne muscular dystrophy (DMD). The trial demonstrated a statistically significant 3.8-second improvement in Time-to-Rise versus natural history, marking the largest effect observed compared to any approved dystrophin restoration therapy.

Key findings include:

• Dystrophin expression stabilized at 7.8% average, with 88% of boys achieving above 5%
• 28.6% reduction in muscle fibrosis between weeks 24-48
• 50% decline in creatine kinase levels
• Significant improvements in muscle health markers

Following FDA feedback, Wave plans to file a New Drug Application in 2026 for accelerated approval. The company also intends to submit multiple clinical trial applications for other exon skipping programs in 2026, targeting a potential >$2.4 billion market opportunity in the United States.

Wave Life Sciences (WVE) reported its Q4 and full year 2024 financial results, highlighting significant progress across its RNA medicine pipeline. The company ended 2024 with $302.1 million in cash, extending runway into 2027.

Key developments include: dosing initiation in the INLIGHT obesity trial with WVE-007 (data expected 2H 2025); ongoing multi-dosing in RestorAATion-2 trial of WVE-006 for AATD at 200mg; and advancement toward FORWARD-53 48-week DMD data in Q1 2025.

Financial highlights for 2024 include: revenue of $108.3 million (compared to $113.3M in 2023), R&D expenses of $159.7 million (up from $130.0M), and G&A expenses of $59.0 million (increased from $51.3M). The company reported a net loss of $97.0 million for the full year 2024.

Wave Life Sciences (Nasdaq: WVE) has announced it will host a live webcast and conference call on Tuesday, March 4, 2025, at 8:30 a.m. ET to review the company's fourth quarter and full year 2024 financial results and provide business updates.

The clinical-stage biotechnology company, which focuses on RNA medicines to transform human health, will make the webcast accessible through the "Investor Events" section of their website at https://ir.wavelifesciences.com/events-publications/events.

Analysts who wish to participate in the Q&A portion can join via an audio conferencing link that will provide dial-in information upon registration. An archived version of the webcast will be available on the company's website following the live event.

Wave Life Sciences (WVE) has initiated the Phase 1 INLIGHT clinical trial for WVE-007, a novel obesity treatment targeting INHBE mRNA. The trial follows CTA approval and represents Wave's first siRNA to enter clinical development. WVE-007 is designed as a long-acting GalNAc-siRNA treatment with potential once- or twice-yearly dosing, aiming to achieve healthy weight loss by reducing fat while preserving muscle mass.

The INLIGHT trial will evaluate safety, tolerability, pharmacokinetics, and biomarkers in adults with overweight or obesity, focusing on body weight, composition, and metabolic health outcomes. The company expects to deliver proof-of-concept clinical data in 2025, aligning with FDA draft guidance on weight reduction therapeutics.

Wave Life Sciences (WVE) announced key milestones for 2025 across its clinical programs and pipeline. The company has submitted CTAs for the Phase 1 INLIGHT clinical trial of WVE-007, targeting obesity through INHBE inhibition, with proof-of-concept data expected in 2025.

Key developments include positive interim results from the FORWARD-53 study of WVE-N531 for DMD, showing 9.0% mean dystrophin expression. The company is advancing WVE-003 for Huntington's disease, with plans for a Phase 2/3 study and IND submission in 2H 2025. Their RNA editing program WVE-006 for AATD demonstrated first-ever clinical proof-of-mechanism, with multidose data expected in 2025.

The company is well-capitalized with runway into 2027 and expects multiple clinical milestones throughout 2025, including regulatory feedback for WVE-N531 in Q1 2025.